Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity

Cancer Biology and Therapy

Volumn 15, Issue 5, 2014, Pages 623-632

  Ung, Nelson ^a   Putoczki, Tracy L ^a,b   Stylli, Stanley S ^a,c   Ng, Irvin ^a   Mariadason, John M ^d   Chan, Timothy A ^e   Zhu, Hong Jian ^a   Luwor, Rodney B ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cetuximab; Colon cancer; EGFR; STAT3

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; CETUXIMAB; ERLOTINIB; K RAS PROTEIN; PROTEIN INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; STAT3 INHIBITOR; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TYRPHOSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTATIC COLORECTAL CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HETEROGRAFTS; HUMANS; MICE, INBRED BALB C; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 2; STAT3 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 84899809176     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28179     Document Type: Article

References (70)

1. Burgess AW. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008; 26:263-74; PMID:18800267; http://dx.doi.org/10. 1080/08977190802312844
2. Engelman JA, Settleman J. Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 2008; 18:73-9; PMID:18325754; http://dx.doi.org/10.1016/j.gde.2008.01.004 (Pubitemid 351694445)
3. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-65; PMID:11426640; http://dx.doi.org/10.1038/sj. onc.1204082 (Pubitemid 32197693)
4. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232; PMID:7612182; http://dx.doi.org/10.1016/1040- 8428(94)00144-I
5. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr., Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85:1327-33; PMID:8340945; http://dx.doi.org/10.1093/jnci/85.16.1327 (Pubitemid 23249725)
6. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53:4637-42; PMID:8402640 (Pubitemid 23304392)
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45; PMID:15269313; http://dx.doi.org/10.1056/NEJMoa033025 (Pubitemid 38944402)
8. Giusti RM, Shastri K, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14:1296-302; PMID:18316547; http://dx.doi.org/10.1158/1078-0432.CCR-07- 1354 (Pubitemid 351413907)
9. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr., Morse D, Abraham S, Rahman A, Liang C, Lostritto R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10:1212-8; PMID:14977817; http://dx.doi.org/10.1158/1078-0432. CCR-03-0564 (Pubitemid 38365209)
10. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, et al.; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-smallcell lung cancer. J Clin Oncol 2005; 23:5892-9; PMID:16043829; http://dx.doi.org/10.1200/JCO.2005.02.840
11. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355:2733-43; PMID:17192538; http://dx.doi.org/10.1056/NEJMoa064320 (Pubitemid 46021510)
12. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25:3230-7; PMID:17664471; http://dx.doi.org/10.1200/JCO.2006.10.5437 (Pubitemid 47325606)
13. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006; 12:7232-41; PMID:17189394; http://dx.doi.org/10.1158/1078-0432.CCR-06-0658 (Pubitemid 46095394)
14. Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25:587-95; PMID:17290067; http://dx.doi.org/10.1200/JCO.2006. 07.3585 (Pubitemid 350002967)
15. Azzoli CG, Baker S Jr., Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27:6251-66; PMID:19917871; http://dx.doi.org/10.1200/JCO.2009.23.5622
16. Chakravarti A, Loeffler JS, Dyson NJ. Insulinlike growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62:200-7; PMID:11782378 (Pubitemid 34074005)
17. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039-43; PMID:17463250; http://dx.doi.org/10.1126/science.1141478 (Pubitemid 46799492)
18. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008; 27:3944-56; PMID:18297114; http://dx.doi.org/10.1038/onc.2008.19 (Pubitemid 351913636)
19. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011; 3:99ra86; PMID:21900593; http://dx.doi.org/10.1126/ scitranslmed.3002442
20. Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ, Leedman PJ. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 2013; 12:2541-58; PMID:24026012; http://dx.doi.org/10.1158/1535- 7163.MCT-13-0170
21. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
22. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-8; PMID:17363584; http://dx.doi.org/10.1158/0008-5472.CAN-06-4158 (Pubitemid 46548951)
23. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-71; PMID:19114683; http://dx.doi.org/10.1200/JCO.2008.20.8397
24. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, et al. KRAS wildtype state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-15; PMID:17998284; http://dx.doi.org/10.1093/annonc/mdm496 (Pubitemid 351325672)
25. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit L, Killian A, Sesboüé R, Tuech JJ, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96:1166-9; PMID:17375050; http://dx.doi.org/10.1038/sj.bjc.6603685 (Pubitemid 46625066)
26. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385
27. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66:3992-5; PMID:16618717; http://dx.doi.org/10.1158/0008-5472.CAN-06-0191
28. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27:2091-6; PMID:19188670; http://dx.doi.org/10.1200/JCO.2009.21.9170
29. Van Cutsem EJ, Oliveira J; ESMO Guidelines Working Group. Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(Suppl 2):ii33-4; PMID:18456760
30. Duffy MJ, O'Donovan N, Crown J. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev 2011; 37:151-9; PMID:20685042; http://dx.doi.org/10.1016/j.ctrv.2010.07.004
31. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-62; PMID:20619739; http://dx.doi.org/10.1016/S1470-2045(10)70130-3
32. Hawkes E, Cunningham D. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies. J Clin Oncol 2010; 28:e529-31, author reply e532-3; PMID:20679615; http://dx.doi.org/ 10.1200/JCO.2010.29.5626
33. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68:1953-61; PMID:18339877; http://dx.doi.org/10.1158/0008-5472.CAN-07-5659 (Pubitemid 351416582)
34. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15:3184-8; PMID:19366826; http://dx.doi.org/10.1158/1078-0432.CCR-08-2961
35. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4:e7287; PMID:19806185; http://dx.doi.org/10.1371/journal.pone.0007287
36. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. Cell 1999; 98:295-303; PMID:10458605; http://dx.doi.org/10.1016/S0092-8674(00)81959-5 (Pubitemid 29380565)
37. Zhong Z, Wen Z, Darnell JE Jr. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264:95-8; PMID:8140422; http://dx.doi.org/10.1126/ science.8140422 (Pubitemid 24144493)
38. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8:945-54; PMID:11948098 (Pubitemid 35177340)
39. Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol 2008; 19:329-40; PMID:18691663; http://dx.doi.org/10.1016/j. semcdb.2008.07.003
40. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11:595-6; PMID:15937466; http://dx.doi.org/10.1038/nm0605-595
41. Lin Q, Lai R, Chirieac LR, Li C, Thomazy VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K, et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol 2005; 167:969-80; PMID:16192633; http://dx.doi.org/10.1016/S0002-9440(10)61187-X (Pubitemid 41416250)
42. Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, et al. Impact of STAT3 phosphorylation on the clinical effectiveness of anti- EGFR-based therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2013; 12:28-36; PMID:23083634; http://dx.doi.org/10.1016/j.clcc.2012.09.002
43. Haura EB, Sommers E, Song L, Chiappori A, Becker A. A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. J Thorac Oncol 2010; 5:1806-14; PMID:20881637; http://dx.doi.org/10.1097/JTO.0b013e3181f38f70
44. Bonner JA, Yang ES, Trummell HQ, Nowsheen S, Willey CD, Raisch KP. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother Oncol 2011; 99:339-43; PMID:21704410; http://dx.doi.org/10.1016/j.radonc.2011.05.070
45. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, Grandis JR. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 2002; 13:355-62; PMID:12193474
46. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY, Hung MC. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005; 7:575-89; PMID:15950906; http://dx.doi.org/ 10.1016/j.ccr.2005.05.007 (Pubitemid 40799250)
47. Sen M, Joyce S, Panahandeh M, Li C, Thomas SM, Maxwell J, Wang L, Gooding WE, Johnson DE, Grandis JR. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 2012; 18:4986-96; PMID:22825581; http://dx.doi.org/10.1158/1078-0432.CCR-12-0792
48. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 2009; 106:9435-40; PMID:19478061; http://dx.doi.org/10.1073/pnas.0900571106
49. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Oledzki J, Ostrowski J. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One 2010; 5: e13091; PMID:20957034; http://dx.doi.org/10.1371/annotation/8c585739-a354-4fc9-a7d0-d5ae26fa06ca
50. Zou TT, Selaru FM, Xu Y, Shustova V, Yin J, Mori Y, Shibata D, Sato F, Wang S, Olaru A, et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002; 21:4855-62; PMID:12101425; http://dx.doi.org/10.1038/sj.onc. 1205613 (Pubitemid 34879462)
51. Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Karttunen TJ, Tuppurainen K, Davalos V, et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene 2007; 26:312-20; PMID:16819509; http://dx.doi.org/10.1038/sj.onc. 1209778 (Pubitemid 46095743)
52. Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y, Aburatani H. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer 2012; 106:126-32; PMID:22095227; http://dx.doi.org/10.1038/bjc.2011.505
53. Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK, Sica GL, Ramalingam SS, Curran WJ, Khuri FR, Deng X. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther 2013; 12:2200-12; PMID:23894143; http://dx.doi.org/10.1158/1535-7163.MCT-13-0095
54. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari PM. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009; 15:1585-92; PMID:19190133; http://dx.doi.org/10.1158/1078-0432. CCR-08-2068
55. Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10:784-93; PMID:14760102; http://dx.doi.org/10. 1158/1078-0432.CCR-1100-03 (Pubitemid 38174017)
56. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGFbinding proteins. J Clin Invest 2008; 118:2609-19; PMID:18568074 (Pubitemid 351949788)
57. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti- EGFR monoclonal antibody cetuximab. Cancer Res 2007; 67:8240-7; PMID:17804738; http://dx.doi.org/10.1158/ 0008-5472.CAN-07-0589 (Pubitemid 47395161)
58. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61:5090-101; PMID:11431346 (Pubitemid 32681540)
59. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 2009; 8:696-703; PMID:19276677; http://dx.doi.org/10.4161/cbt.8.8.7903
60. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007; 67:5779-88; PMID:17575145; http://dx.doi.org/10.1158/0008-5472.CAN-06-3020 (Pubitemid 46985011)
61. Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, Polakiewicz RD, Kinzler KW, Vogelstein B, Velculescu VE, et al. Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci U S A 2007; 104:4060-4; PMID:17360477; http://dx.doi.org/10.1073/pnas.0611665104 (Pubitemid 47181578)
62. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, et al. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc Natl Acad Sci U S A 2014; 111:1114-9; PMID:24395800; http://dx.doi.org/10.1073/pnas.1319551111
63. Su F, Ren F, Rong Y, Wang Y, Geng Y, Wang Y, Feng M, Ju Y, Li Y, Zhao ZJ, et al. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res 2012; 14:R38; PMID:22394684; http://dx.doi.org/10.1186/bcr3134
64. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptorexpressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003; 22:2812-22; PMID:12743604; http://dx.doi.org/10.1038/sj.onc.1206388 (Pubitemid 36609595)
65. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res 2003; 9:4340-6; PMID:14555504 (Pubitemid 37248389)
66. Luwor RB, Baradaran B, Taylor LE, Iaria J, Nheu TV, Amiry N, Hovens CM, Wang B, Kaye AH, Zhu HJ. Targeting Stat3 and Smad7 to restore TGF-β cytostatic regulation of tumor cells in vitro and in vivo. Oncogene 2013; 32:2433-41; PMID:22751114; http://dx.doi.org/10.1038/onc.2012.260
67. Wang Y, Robledo O, Kinzie E, Blanchard F, Richards C, Miyajima A, Baumann H. Receptor subunitspecific action of oncostatin M in hepatic cells and its modulation by leukemia inhibitory factor. J Biol Chem 2000; 275:25273-85; PMID:10854424; http://dx.doi.org/10.1074/jbc.M002296200
68. Luwor RB, Wang B, Nheu TV, Iaria J, Tsantikos E, Hibbs ML, Sieber OM, Zhu HJ. New reagents for improved in vitro and in vivo examination of TGF-β signalling. Growth Factors 2011; 29:211-8; PMID:21913800; http://dx.doi.org/10. 3109/08977 194.2011.615311
69. Luwor RB, Johns TG, Murone C, Huang HJ, Cavenee WK, Ritter G, Old LJ, Burgess AW, Scott AM. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001; 61:5355-61; PMID:11454674 (Pubitemid 32694909)
70. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6:1-6; PMID:15068665 (Pubitemid 38391943)